Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML. Mylofrance 4 (ALFA1401) (NCT02473146)
The main objective of this study is to assess the efficacy and tolerance of the addition of repeated doses of low doses (3mg/m2) of the antibody-drug conjugate gemtuzumab ozogamicin (Mylotarg®; Pfizer/Wyeth-Ayerst Laboratories) in addition with standard doses of Cytarabine (DepoCyt®; Sigma Tau Pharmaceuticals) in previously untreated patients aged 65 to 80 years with de novo acute myeloblastic leukemia (AML) and non adverse cytogenetics.
The main end point for efficacy is 2 years-event free survival. The secondary efficacy endpoints are CR/Cri rates, cumulative incidence of relapse and overall survival. The secondary endpoints for safety are early death rate (before day 30 and 60), grade 3 to 5 adverse events and severe adverse events, cardiac toxicity and quality of life. Additional secondary endpoints are treatment by covariate interactions with respect to biological characteristics present at diagnosis (CD33 positivity, cytogenetic, molecular abnormalities) or after treatment (Minimal Residual Disease/MDR levels).
This study is an exploratory study. Patients will be allocated at inclusion with a 2/1 ratio either to receive treatment with gemtuzumab ozogamicin (GO) and cytarabine or Idarubicin and cytarabine in a 3+7 regimen similar to the “backbone” ALFA 1200 scheme used concurrently by the ALFA group as treatment of AML patients aged >60 years.
The primary objective is to assess the efficacy of two doses of gemtuzumab ozogamicin during induction and one dose of gemtuzumab ozogamicin during first consolidation in combination with Cytarabine in elderly patients with AML in the non adverse cytogenetics-risk group.
This trial is sponsored by Central Hospital (CHV/Centre Hospitalier Général), Versailles, France.
- Condition: Acute Myeloid Leukemia (AML)
- Phase: II & III
- Estimated Enrollment: 225
- Start: June 2015
- Estimated Completion: April 2020
- Last verified: June 2015
Last Editorial review: July 20, 2015
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.